FDA panel recommends mRNA flu vaccine for older adults
A first-of-its-kind flu shot is a step closer to being available to the public after a Food and Drug Administration (FDA) advisory panel voted Thursday to recommend Moderna’s mRNA-based vaccine for approval.
The FDA’s independent vaccine advisors voted unanimously 9-0 that the benefits outweigh the risks for Moderna’s mFlusiva shot in people ages 50 to 64 as well as 65 and older.
Moderna is seeking...
이 뉴스, 독자들은 어떻게 느꼈나요?
첫 반응을 남겨보세요로그인하면 감정 반응에 참여할 수 있어요.
공식 발표 ↔ 진영별 보도
Agency Information Collection Activities; Proposed Collection; Comment Request; Extralabel Drug Use in Animals
SpecGx LLC; Withdrawal of Approval of Abbreviated New Drug Application for Methylphenidate Hydrochloride Extended-Release Tablets, 27 Milligrams, 36 Milligrams, and 54 Milligrams
Advisory Committee; Science Board to the Food and Drug Administration; Renewal
FDA panel recommends mRNA flu vaccine for older adults
FDA panel gives nod to Moderna flu shot
FDA panel backs first-of-its-kind flu vaccine using mRNA technology
STAT+: FDA advisory panel endorses Moderna mRNA flu vaccine that was subject of controversy
FDA panel considers a first-of-its-kind flu vaccine using mRNA technology